Prema "NOTICE TO STAKEHOLDERS WITHDRAWAL OF THE UNITED KINGDOM AND EU RULES FOR MEDICINAL PRODUCTS FOR HUMAN USE AND VETERINARY MEDICINAL PRODUCTS" UK QP može puštati serije lijeka u promet do kraja prijelaznog razdoblja 31.12.2020.
During the transition period, EU pharmaceutical law as laid out in the ‘acquis communautaire' will be applicable to the UK.
This means that pharmaceutical companies have until 31 December 2020 to make the necessary changes to ensure that their centrally and nationally authorised medicines comply with EU law and can remain on the EU market.
For example, the following entities can still be located in the UK until 31 December 2020: ....companies' manufacturing and batch release sites.
Prema "NOTICE TO STAKEHOLDERS WITHDRAWAL OF THE UNITED KINGDOM AND EU RULES FOR MEDICINAL PRODUCTS FOR HUMAN USE AND VETERINARY MEDICINAL PRODUCTS" UK QP može puštati serije lijeka u promet do kraja prijelaznog razdoblja 31.12.2020.
Evo i link: https://www.ema.europa.eu/en/about-us/brexit-uk-withdrawal-eu/brexit-related-guidance-companies gdje kaže isto tako:
During the transition period, EU pharmaceutical law as laid out in the ‘acquis communautaire' will be applicable to the UK.
This means that pharmaceutical companies have until 31 December 2020 to make the necessary changes to ensure that their centrally and nationally authorised medicines comply with EU law and can remain on the EU market.
For example, the following entities can still be located in the UK until 31 December 2020: ....companies' manufacturing and batch release sites.